A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.

Authors :: Rosenthal A
Kumar S
Hofmeister C
Laubach J
Vij R
Dueck A
Gano K
Stewart AK
Source :: British journal of haematology [Br J Haematol] 2016 Jul; Vol. 174 (2), pp. 323-5. Date of Electronic Publication: 2015 Sep 25.
Publication Year :: 2016

Subjects :: Aged
Aurora Kinases antagonists & inhibitors
Azepines adverse effects
Bortezomib adverse effects
Female
Humans
Male
Middle Aged
Multiple Myeloma complications
Multiple Myeloma pathology
Protein Kinase Inhibitors therapeutic use
Pyrimidines adverse effects
Recurrence
Treatment Outcome
Azepines administration & dosage
Bortezomib administration & dosage
Multiple Myeloma drug therapy
Pyrimidines administration & dosage

Full Text Access

Tools